Identification of Biomarkers for Early Detection of Pancreatic Cancer

NCT00897494 | Completed

• 4 other identifiers: CDR0000479140P30CA022453WSU-C-2737WSU-013105MP2E
• Study Type: observational
• Target: 75
• Locations: 1 country
• Sites: 1

Brief Summary

RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer. PURPOSE: This laboratory study is examining blood samples from patients with cancer to identify biomarkers that may help in the early detection of pancreatic cancer.

Conditions

Pancreatic Cancer

Keywords

stage I pancreatic cancer; stage II pancreatic cancer; stage III pancreatic cancer; stage IV pancreatic cancer

Outcome Measures

Primary Outcomes (2)

• Identification of specific proteins of interest to evaluate for their potential role as markers for pancreatic cancer

  Upon collection when patient agrees to provide a one time venous blood collection

• Analysis of serum proteins directly by mass spectrometry to identify new biomarkers of pancreatic cancer that can be used for early diagnosis

  After separation from the plasma

Interventions

protein expression analysis GENETIC

Venous blood collection

laboratory biomarker analysis OTHER

Venous blood collection

mass spectrometry OTHER

Venous blood collection

surface-enhanced laser desorption/ionization-time of flight mass spectrometry OTHER

Venous blood collection

Eligibility Criteria

• Age: 18 Years - 120 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Venous blood collection samples from newly dianosed

DISEASE CHARACTERISTICS: * Diagnosis of pancreatic cancer * Newly diagnosed disease * Planning to undergo surgery or other treatment for pancreatic cancer at Karmanos Cancer Institute or its affiliates PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * See Disease Characteristics

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

• Barbara Ann Karmanos Cancer Institute: lead
• National Cancer Institute (NCI): collaborator

Study Sites (1)

Barbara Ann Karmanos Cancer Institute

Detroit, Michigan, 48201-1379, United States

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

Venous blood

MeSH Terms

Conditions

Pancreatic Neoplasms

Interventions

Mass Spectrometry; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization

Condition Hierarchy (Ancestors)

Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Endocrine Gland Neoplasms; Digestive System Diseases; Pancreatic Diseases; Endocrine System Diseases

Intervention Hierarchy (Ancestors)

Chemistry Techniques, Analytical; Investigative Techniques

Study Officials

• Fazlul Sarkar, MD

  Barbara Ann Karmanos Cancer Institute

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 9, 2009
• First Posted: May 12, 2009
• Study Start: February 1, 2005
• Primary Completion: November 1, 2009
• Study Completion: April 1, 2011
• Last Updated: March 9, 2016

Record last verified: 2016-03

Locations

US (1)